RxDoctor Payments Data

Preethi Krishnan, MD

Family Medicine · Oklahoma City, OKNPI 1861611675

Payments from drug & device makers

$7,863in general payments, 2019–2025

Across 523 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$988
  • Pfizer$925
  • Novo Nordisk$791
  • Boehringer Ingelheim$758
  • AstraZeneca$661
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$7,854100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,863 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$70,592
Medicare patients
166
Services billed
956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide65$68,271
JardianceEmpagliflozin65$54,924
OzempicSemaglutide41$48,554
EliquisApixaban32$26,317
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$25,874
TrulicityDulaglutide18$24,092
Soliqua 100-33Insulin Glargine/Lixisenatide20$22,607
XareltoRivaroxaban18$19,209
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$15,583
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$5,484
Humalog Kwikpen U-100Insulin Lispro11$4,546
SynjardyEmpagliflozin/Metformin Hcl12$4,113
Tresiba Flextouch U-100Insulin Degludec11$2,917
Atorvastatin Calcium191$2,897
Novolog FlexpenInsulin Aspart11$2,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$988$92,36383 claims
Boehringer IngelheimJardiance, Synjardy$758$59,03777 claims
Novo NordiskOzempic$791$48,55441 claims
PfizerEliquis$925$26,31732 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$119$22,60720 claims
Johnson & JohnsonXarelto$26$19,20918 claims
GSKTrelegy Ellipta$233$15,58314 claims
AbbVieSynthroid$1,373$1,24928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →